Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities researchers at Wedbush cut their Q1 2021 earnings estimates for Ultragenyx Pharmaceutical in a report released on Monday, April 12th. Wedbush analyst L. Chico now expects that the biopharmaceutical company will post earnings per share of ($1.37) for the quarter, down from their previous forecast of ($1.19). Wedbush has a “Neutral” rating and a $130.00 price objective on the stock. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s Q2 2021 earnings at ($1.37) EPS, Q3 2021 earnings at ($1.35) EPS, Q4 2021 earnings at ($3.14) EPS, FY2021 earnings at ($7.24) EPS, FY2022 earnings at ($3.75) EPS, FY2023 earnings at ($1.76) EPS, FY2024 earnings at $0.76 EPS and FY2025 earnings at $3.12 EPS.
Other analysts have also recently issued reports about the company. Zacks Investment Research cut Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating and set a $152.00 price objective on the stock. in a research report on Wednesday, February 17th. SVB Leerink lifted their price objective on Ultragenyx Pharmaceutical from $115.00 to $178.00 and gave the company an “outperform” rating in a research report on Tuesday, February 16th. Piper Sandler boosted their price target on Ultragenyx Pharmaceutical from $165.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, February 12th. Stifel Nicolaus began coverage on Ultragenyx Pharmaceutical in a research report on Monday, March 1st. They issued a “buy” rating and a $179.00 price target on the stock. Finally, Credit Suisse Group boosted their price target on Ultragenyx Pharmaceutical from $64.00 to $99.00 and gave the stock a “neutral” rating in a research report on Monday, January 25th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the stock. Ultragenyx Pharmaceutical presently has a consensus rating of “Hold” and an average price target of $132.50.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, February 11th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.06) by ($0.28). The firm had revenue of $91.54 million for the quarter, compared to the consensus estimate of $71.15 million. Ultragenyx Pharmaceutical had a negative net margin of 119.19% and a negative return on equity of 50.69%.
In other Ultragenyx Pharmaceutical news, SVP Theodore Alan Huizenga sold 732 shares of the business’s stock in a transaction on Monday, March 1st. The shares were sold at an average price of $138.17, for a total transaction of $101,140.44. Following the completion of the sale, the senior vice president now directly owns 17,276 shares in the company, valued at approximately $2,387,024.92. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Emil D. Kakkis sold 30,000 shares of the business’s stock in a transaction on Monday, March 1st. The shares were sold at an average price of $141.80, for a total transaction of $4,254,000.00. Following the sale, the chief executive officer now owns 596,941 shares of the company’s stock, valued at $84,646,233.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 54,245 shares of company stock valued at $7,637,704. 8.20% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in RARE. Price T Rowe Associates Inc. MD raised its stake in Ultragenyx Pharmaceutical by 13.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,470,492 shares of the biopharmaceutical company’s stock valued at $1,311,000,000 after buying an additional 1,121,763 shares during the last quarter. Norges Bank purchased a new stake in Ultragenyx Pharmaceutical during the 4th quarter valued at $77,444,000. BlackRock Inc. raised its stake in Ultragenyx Pharmaceutical by 9.9% during the 4th quarter. BlackRock Inc. now owns 5,287,476 shares of the biopharmaceutical company’s stock valued at $731,947,000 after buying an additional 478,279 shares during the last quarter. Baker BROS. Advisors LP bought a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at $61,524,000. Finally, Emerald Advisers LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at $31,406,000.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders.
Further Reading: FinTech
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.